These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 16018737)

  • 1. Antisense oligonucleotides as therapeutics for hyperlipidaemias.
    Crooke RM
    Expert Opin Biol Ther; 2005 Jul; 5(7):907-17. PubMed ID: 16018737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antisense technology: an emerging platform for cardiovascular disease therapeutics.
    Lee RG; Crosby J; Baker BF; Graham MJ; Crooke RM
    J Cardiovasc Transl Res; 2013 Dec; 6(6):969-80. PubMed ID: 23856914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-sense oligonucleotide therapies for the treatment of hyperlipidaemia.
    Wierzbicki AS; Viljoen A
    Expert Opin Biol Ther; 2016 Sep; 16(9):1125-34. PubMed ID: 27248482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia.
    Thomas T; Ginsberg H
    Curr Atheroscler Rep; 2010 Jan; 12(1):58-65. PubMed ID: 20425272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Emerging LDL therapies: Mipomersen-antisense oligonucleotide therapy in the management of hypercholesterolemia.
    Toth PP
    J Clin Lipidol; 2013; 7(3 Suppl):S6-10. PubMed ID: 23642326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline.
    Hennessy EJ; Moore KJ
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):247-54. PubMed ID: 23743768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of lipoprotein metabolism by antisense technology: preclinical drug discovery methodology.
    Crooke RM; Graham MJ
    Methods Mol Biol; 2013; 1027():309-24. PubMed ID: 23912993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mipomersen, an antisense apolipoprotein B synthesis inhibitor.
    Bell DA; Hooper AJ; Burnett JR
    Expert Opin Investig Drugs; 2011 Feb; 20(2):265-72. PubMed ID: 21210756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future challenges for microsomal transport protein inhibitors.
    Wierzbicki AS; Hardman T; Prince WT
    Curr Vasc Pharmacol; 2009 Jul; 7(3):277-86. PubMed ID: 19601852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans.
    Graham MJ; Lee RG; Bell TA; Fu W; Mullick AE; Alexander VJ; Singleton W; Viney N; Geary R; Su J; Baker BF; Burkey J; Crooke ST; Crooke RM
    Circ Res; 2013 May; 112(11):1479-90. PubMed ID: 23542898
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current and future pharmacologic options for the management of patients unable to achieve low-density lipoprotein-cholesterol goals with statins.
    El Harchaoui K; Akdim F; Stroes ES; Trip MD; Kastelein JJ
    Am J Cardiovasc Drugs; 2008; 8(4):233-42. PubMed ID: 18690757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defects of lipoprotein metabolism in familial combined hyperlipidaemia.
    de Graaf J; Stalenhoef AF
    Curr Opin Lipidol; 1998 Jun; 9(3):189-96. PubMed ID: 9645500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides.
    Graham MJ; Lee RG; Brandt TA; Tai LJ; Fu W; Peralta R; Yu R; Hurh E; Paz E; McEvoy BW; Baker BF; Pham NC; Digenio A; Hughes SG; Geary RS; Witztum JL; Crooke RM; Tsimikas S
    N Engl J Med; 2017 Jul; 377(3):222-232. PubMed ID: 28538111
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligonucleotides: the state of the art.
    Aboul-Fadl T
    Curr Med Chem; 2005; 12(19):2193-214. PubMed ID: 16178780
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA-targeted therapeutics in cancer clinical trials: Current status and future directions.
    Barata P; Sood AK; Hong DS
    Cancer Treat Rev; 2016 Nov; 50():35-47. PubMed ID: 27612280
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
    Bard JM; Parra HJ; Douste-Blazy P; Fruchart JC
    Metabolism; 1990 Mar; 39(3):269-73. PubMed ID: 2106607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Interaction between genes and diet as a determinant of the plasma levels of cholesterol].
    López Miranda J; Ordovás JM; Pérez Jiménez F
    Med Clin (Barc); 1998 Oct; 111(14):546-51. PubMed ID: 9859082
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.